FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
CO:05:4 | Natural language processing reveals demographic features, comorbidities, and clinical domains to predict treatment longevity of b/tsDMARDs in psoriatic arthritis Antonio Tonutti1|2, Pierandrea Morandini3, Cosimo Faeti3, Nicoletta Luciano1|2, Saverio D'Amico3, Victor Savevski3, Carlo Selmi1|2 | 1Department of Biomedical Sciences, Humanitas University Pieve Emanuele, Milan, Italy; 2Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 3Artificial Intelligence Unit, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy
84 -
PO:36:245 | Uncovering clinical and demographic differences in major organ involvement versus benign Behçet’s disease: insights from a single-centre study Federica Di Cianni1, Antonello Sulis1, Maria Laura Manca2, Rosaria Talarico1, Marta Mosca1. | 1Rheumatology Unit, University of Pisa, Pisa, Italy; 2Department of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa, Pisa, Italy.
218 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
92 -
PO:11:172 | Not all vasculitis look the same: a difficult diagnosis Marta Arese1|2, Miriam Perino1|2, Sofia Aliprandi1|2, Antonella Murgo2, Maria Gerosa1|2, Roberto Felice Caporali1|2 | 1UOC Reumatologia AOR San Carlo, Potenza; 2Reumatologia Clinica, ASST Gaetano Pini-CTO, Milano, Italy
181 -
PO:08:119 | Infusional Advantage: Rituximab’s Role in Enhancing Adherence in Multimorbid Rheumatoid Arthritis Marco Capodiferro1, Daniele Domanico1, Angelica Napoletano1, Giulia Righetti2, Patrizia Suppressa2, Vincenzo Venerito1, Giuseppe Lopalco1, Florenzo Iannone1, Fabio Cacciapaglia1|2 | 1Rheumatology Unit, Department of Precision and Regenerative Medicine and Jonian Area DiMePRe-J University of Bari, Italy; 2Department of Medicine and Surgery, Miulli General Hospital Acquaviva delle Fonti - LUM University Casamassima Bari Acquaviva delle Fonti, Bari, Italy
39 -
PO:19:281 | Mitochondrial dysfunction in Still’s disease: a preliminary analysis of mtDNA copy number and TFAM expression Ludovica Manisera1, Francesca Giansanti2, Andrea Latini3, Francesca Lotito4, Serena Colafrancesco5, Angelica Gattamelata6, Fabrizio Conti7, Cinzia Ciccacci8, Roberta Priori9 | 1|6|7|9La Sapienza, Roma; 2|3|4|8Unicamillus, Roma; 5Humanitas, Milano, Italy
213 -
PO:08:124 | An exploratory analysis of risk factors for methotrexate-associated osteopathy: a retrospective study Federico Aldegheri1, Francesca Ruzzon1, Matteo Appoloni1, Maurizio Rossini1, Giovanni Adami1, Davide Gatti1, Ombretta Viapiana1, Angelo Fassio1 | 1Università di Verona, Italy
67 -
PO:36:243 | Drug survival, discontinuation reasons and disease activity in patients with Behçet's disease treated with infliximab - a real-life study Antonello Sulis1, Federica Di Cianni1, Maria Laura Manca2, Rosaria Talarico1, Marta Mosca1. | 1Rheumatology Unit of Pisa, University of Pisa, Pisa, Italy, Pisa, Italy; 2Department of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa, Italy, Pisa, Italy.
206
